Back to Search Start Over

Defining the molecular response to ischemia-reperfusion injury and remote ischemic preconditioning in human kidney transplantation.

Authors :
Nordström J
Badia-I-Mompel P
Witasp A
Schwarz A
Evenepoel P
Moor MB
Wennberg L
Saez-Rodriguez J
Wernerson A
Olauson H
Source :
PloS one [PLoS One] 2024 Oct 29; Vol. 19 (10), pp. e0311613. Date of Electronic Publication: 2024 Oct 29 (Print Publication: 2024).
Publication Year :
2024

Abstract

Background: Ischemia-reperfusion injury (IRI) inevitably occurs during kidney transplantation and extended ischemia is associated with delayed graft function and poor outcomes. Remote ischemic preconditioning (RIPC) is a simple, noninvasive procedure aimed at reducing IRI and improving graft function. Experimental studies have implicated the kynurenine pathway as a protective mechanism behind RIPC.<br />Methods: First, paired biopsies from 11 living kidney donors were analyzed to characterize the acute transcriptomic response to IRI. Second, 16 living kidney donors were subjected to either RIPC (n = 9) or no pretreatment (n = 7) to evaluate the impact of RIPC on the transcriptomic response to IRI. Finally, the effect of RIPC on plasma metabolites was analyzed in 49 healthy subjects.<br />Results: There was a robust immediate response to IRI in the renal transcriptomes of living-donor kidney transplantation, including activation of the mitogen-activated protein kinase (MAPK) and epidermal growth factor receptor (EGFR) pathways. Preconditioning with RIPC did not significantly alter the transcriptomic response to IRI or the concentration of plasma metabolites.<br />Conclusions: The present data validate living-donor kidney transplantation as a suitable model for mechanistic studies of IRI in human kidneys. The failure of RIPC to alter transcriptomic responses or metabolites in the kynurenine pathway raises the question of the robustness of the standard procedure used to induce RIPC, and might explain the mixed results in clinical trials evaluating RIPC as a method to attenuate IRI.<br />Competing Interests: J.S.R. reports funding from GSK and Sanofi and fees from Travere Therapeutics and Astex. This does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development, or marketed products associated with this research to declare.<br /> (Copyright: © 2024 Nordström et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)

Details

Language :
English
ISSN :
1932-6203
Volume :
19
Issue :
10
Database :
MEDLINE
Journal :
PloS one
Publication Type :
Academic Journal
Accession number :
39471208
Full Text :
https://doi.org/10.1371/journal.pone.0311613